Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2003

View Archived Issues

Schering sells stake in Oy Leiras to Nycomed

Pfizer to continue Pharmacia's collaboration with Vicuron

Diabact licenses Rapinyl to Kyowa Hakko

Xoma provides review of results for the first quarter

MCH antagonists in early development for obesity and related disorders at Schering-Plough

Schering-Plough researchers design new adenosine A2A antagonists for Parkinson's disease

Neurogen describes new NPY Y5 receptor modulators in recent patent literature

New IMPDH inhibitors, their preparation and use reported by Celltech R&D

Novel isoflavones with utility in hormone balance disorders, cancer, inflammation, etc.

New pyrrolidine-based FTase inhibitors under study at Wyeth

Applied Research Systems presents a novel series of prostanoid EP2/EP4 modulators

Antibacterial isoxazoles prepared and tested at AstraZeneca

Boehringer Ingelheim patent covers novel cytokine production inhibitors

Lipid-lowering effects of ezetimibe in hypercholesterolemia

Effective use of anidulafungin in patients with invasive candidiasis

Strong bactericidal activity found for oritavancin against clinical isolates

Aripiprazole is safe and improves psychotic symptoms in Alzheimer's dementia

New data on vardenafil reported at the American Geriatrics Society meeting

Milestone achieved in PROCARDIS consortium study

Bioenvision signs agreement with Penn for clofarabine

FDA approval to export DB-289 for malaria trial in Thailand

Advisory committee recommends approval of Xolair

Important European launch reported for Hepsera

Electrophysiological effects of drug selectively targeting I(Kur) in myocytes from AF patients

Butanediol esters as potential new bone resorption inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...